Navigation Links
Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
Date:10/22/2007

Dr. Rene Bruno Will Present on the Value of Clinical Trial Simulations to

Predict Efficacy and Survival Benefit of Anticancer Agents

MOUNTAIN VIEW, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Rene Bruno, Ph.D., managing director, Strategic Consulting Services, Europe, has been invited to speak to academics, regulators, and members of the Chinese pharmaceutical industry attending the International Symposium in Quantitative Pharmacology in Drug Development and Regulation. The symposium will be held in Nanjing China at the International Conference Hotel from October 29-31, 2007.

Dr. Bruno will join other leading experts from industry, government and academia in a scientific program that will discuss the latest methodologies in pharmacometrics, focusing on pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation in drug development, regulation and clinical applications. The symposium will also provide a forum for scientific discussion and collaborative exchange on model-based approaches in drug development. Dr. Bruno's presentation, discussing a model-based approach to support drug development in oncology, will be part of a session focusing on the theory and applications of model-based drug development. The presentation, entitled "Clinical Trial Simulations to Predict Efficacy and Survival Benefit of Anticancer Agents", will take place on October 29, 2007. Dr. Bruno also serves on the symposium's international advisory committee.

"Model-based drug development continues to grow as a value-added method for optimizing decisions in the drug development process," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development is benefiting from the quantitative application of drug-disease models to simulate expected clinical re
'/>"/>

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Why companies dont get invited to the DEMO conference
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013   Oligomerix, Inc. ... of disease modifying therapeutics for Alzheimer,s disease (AD) ... of its Series B financing, which includes both ... that would represent approximately $2.8M in new investments ... investors supported the raise. Funding ...
(Date:5/22/2013)... 2013 Genedata, a leading provider ... discovery, and life science research, today announced AB ... as its bioinformatics platform for strain genome data ... provide AB Enzymes, one of the world’s oldest ... of Genedata Selector accompanied by bioinformatics consulting services. ...
(Date:5/22/2013)... MN (PRWEB) May 22, 2013 ... Medical Supplies Pty Ltd are pleased to announce ... is the Australian and New Zealand distributor of DrugCheck® ... V8 Supercar Team participated in the Austin 400 May ... entered into an agreement that involves each car of ...
(Date:5/22/2013)... The ability to sequence genomes has ... encode. There are now a suite of applications ... protected fragments) that dramatically expand our ability to ... Dr. Jonathan Weissman, an Investigator with the University ... Institute, who will present recent applications of their ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2
... 3 Varian, Inc.,(NasdaqGS: VARI) announced today ... detectors (ELSD) for conventional and high speed ... and solvent,compatibility, and excellent baseline stability, Varian ... RI detectors for busy pharmaceutical,and analytical laboratories. ...
... Amarin Corporation plc,(NASDAQ: AMRN ) today ... license with,Scarista Limited ("Scarista") for the development ... portfolio in the field of lipid,science. This ... lipid-based development programs including AMR101 and its ...
... Spiral lead offers flexibility for placement in small, medium and ... ... March 3 Boston Scientific,Corporation (NYSE: BSX ) today announced ... with cardiac resynchronization therapy,defibrillators and cardiac resynchronization therapy pacemakers, both of,which ...
Cached Biology Technology:New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3Amarin Secures Global Intellectual Property Rights for Lipid Programs 4Boston Scientific Announces European Approval of New Heart Failure Lead 2Boston Scientific Announces European Approval of New Heart Failure Lead 3
(Date:5/22/2013)... Early screening for prostate cancer could become as easy ... thanks to UC Irvine research published today in the ... After more than a decade of work, UC Irvine ... usable markers for prostate cancer in urine, meaning that ... accuracy and at dramatically lower cost. The same technology ...
(Date:5/21/2013)... concept of "place" is increasingly being considered in ... have a new resource that can help them ... with the places in their lives. , ... new book co-edited by the Pacific Northwest Research ... human-centered approach to conservation. The book is published ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3MU researchers develop radioactive nanoparticles that target cancer cells 2
... Rochelle, NY, May 20, 2009Small synthetic fragments of genetic ... of abnormal proteins; however, these exciting new drug candidates ... side effects. Understanding how siRNA stimulates this undesirable immune ... design siRNA drugs to avoid it are critical topics ...
... “New Strategies for Optimizing CHO Performance,” to feature ... ZAP-CHO during BIO 2009 International Convention in Atlanta, ... / b3c newswire / – InVitria’s Director ... the performance enhancing features of ZAP-CHO, a new ...
... Barron and his group, working with labs in Italy, Germany ... means by which the deadly virus spreads by taking away ... computer simulations, researchers tested more than 100 carbon fullerene, or ... see if they could be used to inhibit a strain ...
Cached Biology News:Strong immune response to new siRNA drugs in development may cause toxic side effects 2InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO 2International team tracks clues to HIV 2International team tracks clues to HIV 3
Recombinant Human HGF...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
... to histochemically detect specific ... pH in cultured cells ... specific marker is only ... (not found in presenescent/quiescent/immortal ...
Recombinant Mouse LIGHT/TNFSF14...
Biology Products: